Analyst downgrade stalls Synageva’s rise
October 07, 2013 at 12:46 PM EDT
A week after Synageva BioPharma Corp. (Nasdaq: GEVA) raised $179 million in a stock offering, one analyst said he believes the stock price has topped out for now, and downgraded his rating as a result...
